Market Summary
USD12.19-0.14
Market Closed-1.14%
RPTX Stock Price
RPTX RSI Chart
RPTX Valuation
RPTX Price/Sales (Trailing)
RPTX Profitability
RPTX Fundamentals
RPTX Revenue
RPTX Earnings
Price Action
52 Week Range
8.0218.68
(Low)(High)
Last 7 days
18.1%
Last 30 days
18.0%
Last 90 days
6.7%
Trailing 12 Months
4.6%
RPTX Financial Health
RPTX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for RPTX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-06-08 | Zinda Michael | acquired | 34,485 | 12.02 | 2,869 | evp, chief scientific officer |
2023-06-07 | Zinda Michael | sold | -77,040 | 12.03 | -6,404 | evp, chief scientific officer |
2023-06-06 | Zinda Michael | sold | -14,448 | 12.04 | -1,200 | evp, chief scientific officer |
2023-01-30 | Zinda Michael | acquired | - | - | 24,550 | evp, chief scientific officer |
2023-01-30 | Segal Lloyd Mitchell | acquired | - | - | 78,550 | president and ceo |
2023-01-30 | Forte Steve | acquired | - | - | 24,530 | evp, chief financial officer |
2023-01-30 | Koehler Maria | acquired | - | - | 26,450 | evp, chief medical officer |
2022-12-29 | Jerel Davis | acquired | - | - | 4,254 | - |
2022-12-29 | Jerel Davis | acquired | - | - | 70,678 | - |
2022-12-20 | Koehler Maria | acquired | 100,040 | 2.06238 | 48,507 | evp, chief medical officer |
Which funds bought or sold RPTX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | new | - | 36,000 | 36,000 | -% |
2023-09-07 | MPM ASSET MANAGEMENT LLC | unchanged | - | 1,659,550 | 23,727,100 | 11.64% |
2023-09-06 | Deep Track Capital, LP | unchanged | - | 2,018,430 | 28,858,100 | 1.34% |
2023-08-22 | CHI Advisors LLC | added | 0.03 | 2,226,890 | 31,726,600 | 9.63% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 0.65 | 13,378 | 176,220 | -% |
2023-08-16 | Nuveen Asset Management, LLC | sold off | -100 | -235,000 | - | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | added | 2.74 | 3,000 | 28,000 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | reduced | -15.57 | -69,898 | 687,890 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | reduced | -2.81 | 551 | 12,812 | -% |
2023-08-14 | CITADEL ADVISORS LLC | added | 2,122 | 2,175,730 | 2,270,760 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Repare Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | deep track capital, lp | 6.50% | 2,727,606 | SC 13G/A | |
| Feb 14, 2023 | biotechnology value fund l p | 10.6% | 4,443,423 | SC 13G/A | |
| Feb 14, 2023 | price t rowe associates inc /md/ | 0.1% | 26,894 | SC 13G/A | |
| Feb 14, 2023 | redmile group, llc | 6.4% | 2,684,396 | SC 13G/A | |
| Feb 13, 2023 | chi advisors llc | 6.67% | 2,800,126 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Jan 06, 2023 | versant venture capital v, l.p. | 1.3% | 563,403 | SC 13D/A | |
| Jun 13, 2022 | versant venture capital v, l.p. | 2.0% | 850,560 | SC 13D/A | |
| Jun 06, 2022 | biotechnology value fund l p | 10.4% | 4,368,757 | SC 13G/A | |
| Feb 14, 2022 | redmile group, llc | 6.7% | 2,789,496 | SC 13G/A |
Recent SEC filings of Repare Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 09, 2023 | 8-K | Current Report | |
| Aug 09, 2023 | 10-Q | Quarterly Report |
Peers (Alternatives to Repare Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AAPL | 2.7T | 383.9B | -3.49% | 14.63% | 28.86 | 7.12 | -0.93% | -4.89% |
MSFT | 2.4T | 211.9B | -3.06% | 31.92% | 32.56 | 11.12 | 6.88% | -0.52% |
GOOG | 1.7T | 289.5B | -1.47% | 30.51% | 27.19 | 5.72 | 4.10% | -15.36% |
AMZN | 1.3T | 538.0B | -4.72% | 10.07% | 101.87 | 2.47 | 10.73% | 12.62% |
| MID-CAP | ||||||||
JBLU | 1.5B | 9.9B | -28.14% | -36.34% | 55.75 | 0.15 | 24.14% | 106.11% |
NYMT | 795.7M | 246.5M | -4.07% | -6.47% | -5.01 | 3.23 | 6.65% | -174.04% |
| SMALL-CAP | ||||||||
TLRY | 1.6B | 627.1M | -7.75% | -14.29% | -1.08 | 2.51 | -0.20% | -204.67% |
PLAY | 1.5B | 2.2B | -10.06% | 7.70% | 11.01 | 0.71 | 38.20% | -10.10% |
MFA | 1.0B | 543.3M | -3.23% | 5.22% | -715.94 | 1.91 | 31.74% | 78.13% |
NKLA | 961.6M | 56.2M | -5.30% | -69.36% | -1.14 | 17.12 | 40.31% | -12.26% |
BYND | 614.9M | 356.8M | -16.65% | -37.31% | -2.19 | 1.72 | -23.03% | 15.53% |
GPRO | 507.0M | 1.0B | -15.90% | -35.94% | -19.18 | 0.49 | -11.34% | -107.10% |
CGC | 462.3M | 453.3M | 100.98% | -69.12% | -0.38 | 1.02 | -16.04% | 55.90% |
INO | 104.1M | 13.7M | -12.49% | -77.75% | -0.62 | 7.62 | 413.65% | 52.51% |
Repare Therapeutics News
Returns for RPTX
Cumulative Returns on RPTX
-28.3%
3-Year Cumulative Returns
Risks for RPTX
What is the probability of a big loss on RPTX?
98.3%
Probability that Repare Therapeutics stock will be more than 20% underwater in next one year
97.1%
Probability that Repare Therapeutics stock will be more than 30% underwater in next one year.
60.2%
Probability that Repare Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does RPTX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Repare Therapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Repare Therapeutics
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
| Revenue | - | - | - | 131,830,000 | 90,500,667 | 49,171,333 | 7,842,000 | 7,600,000 | 964,000 | 890,000 | 664,000 | 135,000 |
| Operating Expenses | 2.0% | 159,842,000 | 156,748,000 | 151,626,000 | 149,407,000 | 142,218,000 | 129,751,000 | 116,260,000 | 97,861,000 | 79,991,000 | 65,368,000 | 54,437,000 |
| S&GA Expenses | 2.4% | 33,091,000 | 32,310,000 | 32,560,000 | 32,260,000 | 30,952,000 | 29,755,000 | 26,213,000 | 23,369,000 | 20,769,000 | 17,400,000 | 14,346,000 |
| R&D Expenses | 1.9% | 126,751,000 | 124,438,000 | 119,066,000 | 117,147,000 | 111,266,000 | 99,996,000 | 90,047,000 | 74,492,000 | 59,222,000 | 47,968,000 | 40,091,000 |
| EBITDA | 100.0% | - | -6,631,000 | -9,956,000 | - | -131,311,000 | -119,852,000 | -106,875,000 | - | - | -63,748,000 | -54,742,000 |
| EBITDA Margin | 100.0% | - | -0.05 | -0.08 | - | -15.93 | -15.28 | -14.06 | - | - | -96.01 | -405 |
| Interest Expenses | - | - | - | 1,966,000 | - | - | - | 240,000 | - | - | - | 216,000 |
| Earnings Before Taxes | 278.3% | 18,724,000 | -10,500,000 | -13,900,000 | -25,972,000 | -133,087,000 | -121,757,000 | -108,586,000 | -96,701,000 | -78,746,000 | -63,748,000 | -54,742,000 |
| EBT Margin | 100.0% | - | -0.08 | -0.11 | -0.29 | -16.15 | -15.53 | -14.29 | -100 | -88.48 | -96.01 | -405 |
| Net Income | 89.4% | -3,084,000 | -29,231,000 | -29,047,000 | -25,679,000 | -132,032,000 | -120,248,000 | -106,908,000 | -93,881,000 | -76,740,000 | -62,233,000 | -53,417,000 |
| Net Income Margin | 100.0% | - | -0.22 | -0.22 | -0.28 | -16.02 | -15.33 | -14.07 | -97.39 | -86.22 | -93.72 | -395 |
| Free Cashflow | 100.0% | - | -2,048,000 | -280,000 | 6,734,000 | -114,255,000 | -102,980,000 | -87,486,000 | -81,251,000 | -68,731,000 | -13,573,000 | -8,321,000 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
| Assets | -10.3% | 302 | 336 | 364 | 409 | 308 | 337 | 369 | 296 | 321 | 339 | 357 | 370 | 382 | 103 |
| Current Assets | -10.3% | 292 | 326 | 354 | 391 | 290 | 319 | 351 | 280 | 309 | 328 | 347 | 361 | 377 | 99.00 |
| Cash Equivalents | -4.9% | 116 | 121 | 160 | 155 | 276 | 305 | 334 | 261 | 294 | 312 | 326 | 348 | 370 | 95.00 |
| Net PPE | -10.7% | 5.00 | 5.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 2.00 | 2.00 |
| Liabilities | -34.0% | 56.00 | 85.00 | 85.00 | 103 | 83.00 | 78.00 | 80.00 | 77.00 | 76.00 | 71.00 | 70.00 | 69.00 | 68.00 | 13.00 |
| Current Liabilities | -34.2% | 53.00 | 81.00 | 79.00 | 62.00 | 39.00 | 34.00 | 35.00 | 23.00 | 23.00 | 12.00 | 11.00 | 10.00 | 10.00 | 4.00 |
| Shareholder's Equity | -2.3% | 245 | 251 | 280 | 306 | 226 | 259 | 288 | 218 | 245 | 268 | 287 | 301 | 314 | - |
| Retained Earnings | -4.4% | -286 | -274 | -239 | -207 | -283 | -245 | -210 | -181 | -151 | -124 | -103 | -88.09 | -74.34 | -49.94 |
| Additional Paid-In Capital | 14.5% | 49.00 | 43.00 | 37.00 | 32.00 | 27.00 | 23.00 | 18.00 | 14.00 | 11.00 | 8.00 | 6.00 | 5.00 | 4.00 | 4.00 |
| Shares Outstanding | 0.0% | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 37.00 | 37.00 | 37.00 | 37.00 | 14.00 | 3.00 | 2.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
| Cashflow From Operations | -422.0% | -7,611 | -1,458 | 322 | 9,221 | -111,710 | -101,575 | -85,796 | -78,005 | -65,336 | -10,594 | -6,084 | -2,483 | 11,770 | -33,218 | -18,429 | -23,404 | -6,464 |
| Share Based Compensation | 7.2% | 22,518 | 20,998 | 19,691 | 18,449 | 17,089 | 15,527 | 12,829 | 9,939 | 7,117 | 4,323 | 2,537 | 1,729 | 985 | 795 | 511 | 508 | 372 |
| Cashflow From Investing | 16.2% | -153,208 | -182,867 | -175,778 | -210,234 | -1,693 | -501 | -1,676 | -10,525 | -10,609 | -10,505 | -9,763 | -1,259 | -967 | -1,272 | -1,304 | -724 | -760 |
| Cashflow From Financing | -15.7% | 887 | 1,052 | 880 | 95,277 | 95,371 | 95,615 | 95,557 | 1,284 | -774 | 247,803 | 247,842 | 247,553 | 331,496 | 109,960 | 103,243 | 328,992 | 41,990 |
RPTX Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Collaboration agreements | $ 30,249 | $ 679 | $ 35,927 | $ 1,087 |
| Operating expenses: | ||||
| Research and development, net of tax credits | 33,788 | 31,475 | 65,618 | 57,933 |
| General and administrative | 8,719 | 7,938 | 17,248 | 16,717 |
| Total operating expenses | 42,507 | 39,413 | 82,866 | 74,650 |
| Loss from operations | (12,258) | (38,734) | (46,939) | (73,563) |
| Other income (expense), net | ||||
| Realized and unrealized (loss) gain on foreign exchange | (41) | 141 | (97) | 124 |
| Interest income | 3,489 | 544 | 6,916 | 673 |
| Other expense | (26) | (11) | (41) | (19) |
| Total other income, net | 3,422 | 674 | 6,778 | 778 |
| Loss before income taxes | (8,836) | (38,060) | (40,161) | (72,785) |
| Income tax expense | (3,110) | (33) | (6,726) | (65) |
| Net loss | (11,946) | (38,093) | (46,887) | (72,850) |
| Unrealized (loss) gain on available-for-sale marketable securities | (189) | 0 | 4 | 0 |
| Total other comprehensive (loss) gain | (189) | 0 | 4 | 0 |
| Comprehensive loss | $ (12,135) | $ (38,093) | $ (46,883) | $ (72,850) |
| Net loss per share attributable to common shareholders--basic | $ (0.28) | $ (0.91) | $ (1.11) | $ (1.74) |
| Net loss per share attributable to common shareholders--diluted | $ (0.28) | $ (0.91) | $ (1.11) | $ (1.74) |
| Weighted-average common shares outstanding-basic | 42,089,530 | 41,899,509 | 42,065,237 | 41,880,666 |
| Weighted-average common shares outstanding-diluted | 42,089,530 | 41,899,509 | 42,065,237 | 41,880,666 |
RPTX Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $ 115,544 | $ 159,521 |
| Marketable securities | 165,148 | 184,420 |
| Income tax receivable | 1,751 | 0 |
| Other current receivables | 5,281 | 4,323 |
| Prepaid expenses | 4,201 | 5,715 |
| Total current assets | 291,925 | 353,979 |
| Property and equipment, net | 4,821 | 4,228 |
| Operating lease right-of-use assets | 4,434 | 5,371 |
| Other assets | 408 | 497 |
| TOTAL ASSETS | 301,588 | 364,075 |
| CURRENT LIABILITIES: | ||
| Accounts payable | 4,893 | 461 |
| Accrued expenses and other current liabilities | 21,628 | 21,645 |
| Operating lease liability, current portion | 2,320 | 2,171 |
| Deferred revenue, current portion | 24,412 | 53,102 |
| Income tax payable | 0 | 1,240 |
| Total current liabilities | 53,253 | 78,619 |
| Operating lease liability, net of current portion | 2,226 | 3,257 |
| Deferred revenue, net of current portion | 695 | 2,682 |
| TOTAL LIABILITIES | 56,174 | 84,558 |
| SHAREHOLDERS’ EQUITY | ||
| Preferred shares, no par value per share; unlimited shares authorized as of June 30, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding as of June 30, 2023, and December 31, 2022, respectively | 0 | 0 |
| Common shares, no par value per share; unlimited shares authorized as of June 30, 2023 and December 31, 2022; 42,093,946 and 42,036,193 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 482,739 | 482,032 |
| Additional paid-in capital | 49,299 | 37,226 |
| Accumulated other comprehensive loss | (424) | (428) |
| Accumulated deficit | (286,200) | (239,313) |
| Total shareholders’ equity | 245,414 | 279,517 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ 301,588 | $ 364,075 |
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.